Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Radius Health (RDUS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,306,520
  • Shares Outstanding, K 45,460
  • Annual Sales, $ 22,110 K
  • Annual Income, $ -254,240 K
  • 36-Month Beta 1.23
  • Price/Sales 60.17
  • Price/Cash Flow N/A
  • Price/Book 6.79

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.25 +4.77%
on 06/28/18
31.92 -10.56%
on 06/20/18
-1.99 (-6.52%)
since 06/15/18
3-Month
27.04 +5.58%
on 06/11/18
36.00 -20.69%
on 04/18/18
-6.58 (-18.73%)
since 04/17/18
52-Week
24.66 +15.77%
on 11/14/17
45.90 -37.80%
on 07/31/17
-14.42 (-33.56%)
since 07/17/17

Most Recent Stories

More News
Radius Health Strengthens Senior Management Team with Appointment of Chhaya Shah as Senior Vice President of Technical Operations

Radius Health, Inc. ("Radius" or the "Company") (Nasdaq:RDUS) today announced the appointment of Chhaya Shah as Senior Vice President of Technical Operations.

RDUS : 28.67 (-0.24%)
X4 Pharmaceuticals Appoints Michael Wyzga as Chair of Board of Directors

X4 Pharmaceuticals, a clinical-stage biotechnology company developing novel CXCR4 allosteric antagonist drug candidates designed to improve immune cell trafficking to treat...

EXAS : 65.13 (+0.73%)
RDUS : 28.67 (-0.24%)
AKBA : 10.57 (+5.17%)
Best Relative Performance in the Biotechnology Industry Detected in Shares of Sage Therapeutic (SAGE , RDUS , ALNY , ICPT , ADRO )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

RDUS : 28.67 (-0.24%)
ALNY : 102.84 (+0.08%)
SAGE : 167.09 (-0.80%)
Why Is Radius Health (RDUS) Down 9.7% Since its Last Earnings Report?

Radius Health (RDUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

RDUS : 28.67 (-0.24%)
Radius Health to Present at the Goldman Sachs 39th Annual Global Healthcare Conference

Radius Health, Inc. (Nasdaq:RDUS) announced today that Jesper Høiland, President and Chief Executive Officer and Pepe Carmona, Senior Vice President and Chief Financial Officer of the Company, will...

RDUS : 28.67 (-0.24%)
Radius to Host Investor Day on June 8, 2018

Radius Health, Inc. (Nasdaq:RDUS) announced today that it will host an Investor Day on Friday, June 8, 2018 in New York City starting at 8:00 a.m. ET. Members of the Radius leadership team will provide...

RDUS : 28.67 (-0.24%)
Watch for Radius Health In to Potentially Rebound After Falling 1.40% Yesterday

Radius Health In (NASDAQ:RDUS) traded in a range yesterday that spanned from a low of $31.18 to a high of $32.11. Yesterday, the shares fell 1.4%, which took the trading range below the 3-day low of...

RDUS : 28.67 (-0.24%)
Tymlos (abaloparatide; Radius Health/Teijin) Drug Overview 2018 - ResearchAndMarkets.com

The "Drug Overview: Tymlos" report has been added to ResearchAndMarkets.com's offering.

TINLY : 17.7800 (-0.39%)
RDUS : 28.67 (-0.24%)
Radius Health (RDUS) Incurs Narrower-Than-Expected Q1 Loss

Radius Health (RDUS) narrower-than-expected loss in the first quarter was encouraging as sales of lead drug Tymlos pick up amid competition.

RDUS : 28.67 (-0.24%)
LLY : 89.61 (+0.61%)
EXEL : 21.37 (+1.42%)
AMGN : 193.61 (-0.65%)
Radius Health Reports First Quarter 2018 Financial and Operating Results and Provides Business Update

First quarter 2018 TYMLOS(R) sales increase to $14.5 million, a 90% increase over the fourth quarter of 2017

RDUS : 28.67 (-0.24%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade RDUS with:

Business Summary

Radius Health Inc. is a science-driven biopharmaceutical company. It is focused on developing novel differentiated therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases. The Company's lead product candidate, abaloparatide (BA058), is in development, in both...

See More

Key Turning Points

2nd Resistance Point 29.64
1st Resistance Point 29.19
Last Price 28.67
1st Support Level 28.42
2nd Support Level 28.10

See More

52-Week High 45.90
Fibonacci 61.8% 37.79
Fibonacci 50% 35.28
Fibonacci 38.2% 32.77
Last Price 28.67
52-Week Low 24.66

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar